Current Report Filing (8-k)

Date : 05/10/2019 @ 10:07PM
Source : Edgar (US Regulatory)
Stock : Marker Therapeutics Inc (MRKR)
Quote : 5.97  -0.02 (-0.33%) @ 10:00PM

Current Report Filing (8-k)

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

May 9, 2019

Date of Report (Date of earliest event reported)

 

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37939 45-4497941
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

3200 Southwest Freeway

Suite 2240

Houston, Texas

  77027
(Address of principal executive offices)   (Zip Code)

 

(713) 400-6400

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common Stock, par value $0.001 per share   MRKR   The Nasdaq Stock Market LLC

  

 

 

 

 

 

Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

(a) The 2019 annual meeting of shareholders of Marker Therapeutics, Inc. (“Marker” or the “Company”) was held on May 9, 2019.

 

(b) At the 2019 annual meeting, the following proposals were voted on by our shareholders:

 

PROPOSAL I:    Election of Directors.

 

Mr. Frederick Wasserman, Mr. David Laskow-Pooley, Mr. John Wilson, Mr. David Eansor, Dr. Juan Vera and Mr. Peter Hoang were each re-elected as Directors, to serve until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death. The votes were as follows: 

   

  For

Abstain/

Withheld

Broker

Non-Votes

Frederick Wasserman 26,358,698 72,045 9,582,310 
David Laskow-Pooley 26,403,527 34,716 9,574,810
John Wilson 24,732,086 1,714,082 9,566,885
David Eansor 26,385,582 30,763 9,596,798
Juan Vera 24,803,475 1,662,268 9,547,310
Peter Hoang 24,814,510 1,651,233 9,596,798

 

PROPOSAL II: To conduct a non-binding advisory vote on executive compensation. The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers as described in the proxy statement. The votes were as follows:

 

FOR 20,672,232
AGAINST 1,953,862
ABSTAIN/WITHHELD 120,074
BROKER NON-VOTES 13,266,885

  

PROPOSAL III: Ratification of the selection of Marcum LLP as the Company’s independent auditors for the year ending December 31, 2019. The Company's stockholders ratified the selection of Marcum LLP as the Company’s independent auditors for the year ending December 31, 2019. The votes were as follows:

 

FOR 35,792,766
AGAINST 160,077
ABSTAIN/WITHHELD 60,210
  36,013,053

 

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 10 th day of May, 2019.

 

 

 

MARKER THERAPEUTICS, INC. 

(Registrant) 

   

BY: 

/s/ Anthony Kim 

 

 

Anthony Kim 

Chief Financial Officer 

  

 

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more Marker Therapeutics Charts.

Marker Therapeutics (NASDAQ:MRKR)
Intraday Stock Chart

Today : Thursday 19 September 2019

Click Here for more Marker Therapeutics Charts.

Latest MRKR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.